RT Conference Proceedings
T1 Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial
A1 Rodriguez-Moreno, J. F.
A1 de Velasco, G.
A1 Alvarez-Fernandez, C.
A1 Collado, R.
A1 Fernandez-Rodriguez, R.
A1 Vazquez Estevez, S.
A1 Virizuela Echaburu, J. A.
A1 Gajate Borau, P.
A1 Font, A.
A1 Lainez, N.
A1 Sevillano Fernandez, E.
A1 Ruiz, S.
A1 Beltran, L.
A1 Rodriguez-Antona, C.
A1 Berraondo, P.
A1 Garcia-Donas, J.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/27617
UL https://hdl.handle.net/10668/27617
LA en
DS RISalud
RD Apr 10, 2025